Your browser doesn't support javascript.
loading
Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.
Morand, Eric F; Abreu, Gabriel; Furie, Richard A; Golder, Vera; Tummala, Raj.
Afiliação
  • Morand EF; Centre for Inflammatory Diseases, Monash University, Melbourne, Victoria, Australia.
  • Abreu G; Biometrics, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Furie RA; Division of Rheumatology, Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, USA.
  • Golder V; Centre for Inflammatory Diseases, Monash University, Melbourne, Victoria, Australia.
  • Tummala R; Clinical Development, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA Raj.Tummala@astrazeneca.com.
Ann Rheum Dis ; 82(5): 639-645, 2023 05.
Article em En | MEDLINE | ID: mdl-36690388
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tulipa / Lúpus Eritematoso Sistêmico Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tulipa / Lúpus Eritematoso Sistêmico Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article